Drugs for Intermittent Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 42)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Budesonide |
Approved |
Phase 4 |
|
51333-22-3 |
63006 5281004 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11Β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
AC-4697
B 7777
B7777_SIGMA
Bidien
Bio-0010
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Budecort Inhaler
Budenofalk
Budeson
Budesónida
budesonide
Budesonide
Budesonide (JAN/USAN/INN)
Budesonide [USAN:INN:BAN:JAN]
Budesonide Easyhaler
Budesonide MMX
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
Cortivent
CPD000058337
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
Entocort
Entocort ec
Entocort EC
Entocort EC (TN)
EU-0100174
Giona Easyhaler
HMS1569H17
|
HMS1921I22
HMS2094I13
HMS501H17
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
Lopac0_000174
LS-187734
LS-7235
MAP-0010
Micronyl
Miflonide
MLS000028507
MLS001077323
MLS002207112
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick_840
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort turbuhaler
Pulmicort Turbuhaler
Respules
Rhinocort
Rhinocort alpha
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S1286_Selleck
S-1320
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
ST51039033
TL8003397
Tridesilon
Uceris
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
|
|
2 |
|
Fluticasone |
Approved, Experimental |
Phase 4 |
|
90566-53-3 |
62924 |
Synonyms:
90566-53-3
AC1NSJZT
AC-456
BIDD:GT0819
C07815
CHEMBL1201396
CID5311101
D07981
Fluticaps
|
Fluticaps (TN)
Fluticason
Fluticasona
fluticasone
Fluticasone
Fluticasone (INN)
Fluticasonum
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
|
|
3 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
4 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
5 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
6 |
|
Hormones |
|
Phase 4 |
|
|
|
7 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
8 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
9 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
10 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
11 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
12 |
|
mometasone furoate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
83919-23-7 |
|
Synonyms:
|
Mometasone furoate anhydrous
|
|
13 |
|
Histamine |
Approved, Investigational |
Phase 3 |
|
51-45-6, 75614-87-8 |
774 |
Synonyms:
.beta.-Imidazolyl-4-ethylamine
[3H]histamine
1avn
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1qft
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-[4-Imidazolyl]ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
51-45-6
53290_FLUKA
5-imidazoleethylamine
5-Imidazoleethylamine
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
beta-Aminoethylimidazole
beta-aminothethylglyoxaline
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
bmse000744
BSPBio_001117
BSPBio_002124
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
histamine
|
Histamine
Histamine (DCF)
Histamine [USAN]
Histamine Base
Histamine, Free Base
Histaminum
Histaminum (TN)
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L000292
L-histamine
Lopac0_000595
Lopac-H-7250
LS-75835
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
nchembio.87-comp54
nchembio714-comp1
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
Spectrum_000845
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
ST073926
STK346752
STOCK5S-55669
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
β-Imidazolyl-4-ethylamine
|
|
14 |
|
Desloratadine |
Approved, Investigational |
Phase 3 |
|
100643-71-8 |
124087 |
Synonyms:
100643-71-8
8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
AC-1279
AC1L3XUD
Aerius
AKOS000280921
Allex
Azomyr
BB_SC-2104
C121345
CHEBI:291342
CHEMBL1172
CID124087
Claramax
Clarinex
Clarinex (TN)
Clarinex Reditabs
Clarinex RediTabs
CPD000149358
D03693
D3787
DB00967
Denosin
Desalex
Descarboethoxyloratadine
Descarboethoxyloratadine acetate
Descarboethoxyoratidine
Desloratadina
desloratadine
|
Desloratadine
Desloratadine (USAN/INN)
Desloratadine [USAN]
Desloratidine
Essex brand of desloratadine
HMS2052H05
HMS2090C06
HMS2093F19
I06-1866
L001025
LS-181814
MLS000559042
MLS000759406
MLS001201801
MolPort-000-883-875
NCGC00159325-02
NCGC00159325-03
NCGC00159325-04
Neoclarityn
NeoClarityn
NSC675447
Opulis
SAM001246545
Sch 34117
Sch-34117
Schering brand of desloratadine
Schering-Plough brand of desloratadine
SMR000149358
STK586537
TL8000065
UNII-FVF865388R
|
|
15 |
|
Glutaral |
Experimental |
Phase 3 |
|
111-30-8 |
3485 |
Synonyms:
1,3-Diformyl propane
1,3-Diformylpropane
1,5-Pentanedial
1,5-Pentanedione
Aldehyd glutarowy
Aldesan
Aldesen
Alhydex
Aqucar
Bactron K31
Bioglan brand OF glutaral
Bode brand OF glutaral
Cahill may roberts brand OF glutaral
Cidex
Cidex 7
Coldcide-25 microbiocide
Dermal brand OF glutaral
Dermatech brand OF glutaral
Dioxopentane
Diswart
Ecolab brand OF glutaral
Gludesin
Glutaclean
Glutaral
Glutaral(usan)
Glutaral, inn, usan
Glutaraldehyd
Glutaraldehyde
GLUTARALDEHYDE, 25% soln
Glutaralum
Glutarate dialdehyde
Glutardialdehyde
Glutarex 28
Glutaric acid dialdehyde
|
Glutaric aldehyde
Glutaric dialdehyde
Glutarol
Glutarol-1,5-pentanedial
Gluteraldehyde
Glutural
Hospex
Johnson and johnson brand OF glutaral
Korsolex
Novaruca
Pentane-1,5-dial
Pentanedial
PENTANEDIAL
Pentanedial, homopolymer
Poly(glutaraldehyde)
Polyglutaraldehyde
Potentiated acid glutaraldehyde
Protectol gda, GT 50
PTD
Relugan GT
Relugan GT 50
Relugan GTW
Sekumatic
Sonacide
Sporicidin
Sterihyde
Sterihyde L
Ucarcide
Ucarcide 225
Ucarcide 250
Ucarset
Verucasep
Veruca-sep
Virsal
|
|
16 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
17 |
|
Cholinergic Antagonists |
|
Phase 3 |
|
|
|
18 |
|
Histamine Antagonists |
|
Phase 3 |
|
|
|
19 |
|
Histamine Phosphate |
|
Phase 3 |
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
20 |
|
Histamine H1 Antagonists |
|
Phase 3 |
|
|
|
21 |
|
Histamine H1 Antagonists, Non-Sedating |
|
Phase 3 |
|
|
|
22 |
|
Cholinergic Agents |
|
Phase 3 |
|
|
|
23 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 2 |
|
21645-51-2 |
|
Synonyms:
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
|
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
|
|
24 |
|
Terbutaline |
Approved |
Phase 2 |
|
23031-25-6 |
5403 |
Synonyms:
(+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol
(+-)-Terbutaline
1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9CI)
23031-25-6
23031-32-5 (Sulfate)
46719-29-3
5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
AB00053548
AC1L1KA2
Aliud brand OF terbutaline sulfate
Alpharma brand OF terbutaline sulfate
Arubendol
Asthmasian
Asthmasian (TN)
Asthmoprotect
AstraZeneca brand OF terbutaline
AstraZeneca brand OF terbutaline sulfate
Azupharma brand OF terbutaline sulfate
BPBio1_000663
BRD-A50157456-065-02-4
Brethaire
Brethine
Brican
Bricanyl
Bricanyl sa
Bricar
Bricaril
Bricyn
BRN 2370513
BSPBio_000601
BSPBio_002066
Butaliret
Butalitab
C07129
CHEMBL1760
CID5403
Contimit
CT Arzneimittel brand OF terbutaline sulfate
CT-Arzneimittel brand OF terbutaline sulfate
D08570
DB00871
Dermapharm brand OF terbutaline sulfate
DivK1c_000078
EINECS 245-385-8
Estedi brand OF terbutaline sulfate
Fatol brand OF terbutaline sulfate
Hexal brand OF terbutaline sulfate
Hoechst brand OF terbutaline sulfate
I01-3464
IDI1_000078
KBio1_000078
KBio2_001510
KBio2_004078
KBio2_006646
KBio3_001566
KBioGR_001539
KBioSS_001510
|
Kendrick brand OF terbutaline sulfate
KWD 2019
KWD-2019
L000594
Lagap brand OF terbutaline sulfate
Lindopharm brand OF terbutaline sulfate
Lopac0_001126
LS-29961
LS-7713
MolPort-003-850-418
Monovent
NCGC00016010-06
NCGC00089821-02
NINDS_000078
Novartis brand OF terbutaline sulfate
Oprea1_823972
PDSP1_000158
PDSP2_000157
Pharma-stern brand OF terbutaline sulfate
Prestwick0_000391
Prestwick1_000391
Prestwick2_000391
Prestwick3_000391
Ratiopharm brand OF terbutaline sulfate
SBB063955
SPBio_001453
SPBio_002522
Spectrum_001030
Spectrum2_001327
Spectrum3_000593
Spectrum4_000870
Spectrum5_001262
Stadapharm brand OF terbutaline sulfate
Taziken
Tedipulmo
Terbasmin
Terbul
Terbutalin
Terbutalin al
Terbutalin ratiopharm
Terbutalin stada
Terbutalin von CT
Terbutalina
Terbutalina [Dcit]
Terbutalina [DCIT]
terbutaline
Terbutaline
Terbutaline (INN)
Terbutaline [INN:BAN]
Terbutaline astrazeneca brand
Terbutaline sulfate
Terbutaline Sulfate
Terbutalino
Terbutalino [INN-Spanish]
Terbutalin-ratiopharm
Terbutalinum
Terbutalinum [INN-Latin]
Terbuturmant
UNII-N8ONU3L3PG
|
|
25 |
|
Olodaterol |
Approved |
Phase 2 |
|
868049-49-4 |
|
Synonyms:
|
26 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
27 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
28 |
|
Antacids |
|
Phase 2 |
|
|
|
29 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
30 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
31 |
|
Adrenergic beta-Agonists |
|
Phase 2 |
|
|
|
32 |
|
Salmeterol xinafoate |
|
Phase 2 |
|
94749-08-3 |
56801 |
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
GR-33343 G
|
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
salmeterol xinafoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent diskus
Serevent Inhaler and Disks
SMR000875207
Ultrabeta
UNII-6EW8Q962A5
|
|
33 |
|
Adrenergic Agonists |
|
Phase 2 |
|
|
|
34 |
|
Adrenergic Agents |
|
Phase 2 |
|
|
|
35 |
|
Fluticasone-Salmeterol Drug Combination |
|
Phase 2 |
|
|
|
36 |
|
Tocolytic Agents |
|
Phase 2 |
|
|
|
37 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
38 |
|
Formoterol Fumarate |
|
Phase 2 |
|
|
|
39 |
|
Sympathomimetics |
|
Phase 2 |
|
|
|
40 |
|
Vaccines |
|
Phase 2 |
|
|
|
41 |
|
Albuterol |
|
Phase 1 |
|
|
|
42 |
|
Pulmonary Surfactants |
|
|
|
|
|
Interventional clinical trials:
(show all 15)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction? |
Completed |
NCT00716963 |
Phase 4 |
Fluticasone propionate (Flovent Diskus) 250 mcg;budesonide 400 mcg |
2 |
Multicenter, Placebo-controlled, Long-term Study of Depigoid Birch 5000 in Adults and Adolescents With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma |
Completed |
NCT01694836 |
Phase 3 |
|
3 |
An Exploratory Study of Mometasone Furoate Nasal Spray in Patients With Moderate-severe Persistent Allergic Rhinitis and Intermittent Asthma: Effects on the Quality of Life Evaluated With the Rhinasthma Questionnaire |
Completed |
NCT00599027 |
Phase 3 |
Mometasone furoate nasal spray (MFNS);Placebo nasal spray |
4 |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Intraseasonal Specific Short-term Immunotherapy With Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract (Depiquick® Birch) in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma |
Completed |
NCT01902992 |
Phase 3 |
Depiquick Birch (DPG103);Placebo |
5 |
Evaluation of the Efficacy and Safety of Desloratadine Syrup in Children Suffering From Seasonal Allergic Rhinitis With or Without Intermittent Asthma |
Completed |
NCT00805324 |
Phase 3 |
Desloratadine |
6 |
A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma |
Completed |
NCT01634958 |
Phase 2 |
|
7 |
A Randomised, Open Label, Five-way Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate and Salmeterol From SERETIDE/ADVAIR 250HFA MDI Alone and With AeroChamber-Max Spacer and VOLUMATIC Both in Their Washed and Unwashed States in Adult Subjects With Mild or Intermittent Asthma |
Completed |
NCT00369993 |
Phase 2 |
fluticasone propionate/salmeterol |
8 |
Randomized, DB, Parallel Group, MC Study to Evaluate the Efficacy and Safety of Four Doses of Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract (Depigoid Birch) in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma |
Completed |
NCT01144429 |
Phase 2 |
|
9 |
A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol "As-needed", or Terbutaline "As-needed" or Regular Use of Budesonide + Terbutaline "As-needed", in Patients With Mild Intermittent Asthma |
Completed |
NCT00989833 |
Phase 2 |
budesonide;terbutaline;budesonide/formoterol |
10 |
Randomised, Double-Blind, Placebo-Controlled, 5-Way Cross-Over Study to Assess the Efficacy (Bronchoprotection) and Safety of a Single Dose of Orally Inhaled BI 1744 CL (2, 5, 10 and 20ug) in Patients With Intermittent Asthma |
Completed |
NCT00928668 |
Phase 2 |
Placebo;Olodaterol (BI1744CL);Olodaterol (BI1744CL);Olodaterol (BI1744CL);Olodaterol (BI1744CL) |
11 |
A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Label Serevent® Diskus® in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma |
Completed |
NCT02433834 |
Phase 2 |
Glycopyrronium MDI;Serevent Diskus 50 μg;Placebo |
12 |
Clinical Exploring Study of Weiyang Yuping Decoction in Preventing Acute Attacks of Mild to Moderate Intermittent Asthma Based on the Theory of "Preventing Disease From Exacerbating" in Chinese Medicine |
Not yet recruiting |
NCT04522726 |
Phase 2 |
Weiyang Yuping Fang |
13 |
Prospective Study to Evaluate the Safety of a 4-month Treatment With Depigoid® Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml) in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Mild Persistent or Intermittent Asthma |
Terminated |
NCT01591343 |
Phase 2 |
|
14 |
A Stepwise, Rising Dose Study of Male Subjects With Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI Compared With Placebo Acu-30™ DPI |
Completed |
NCT00565591 |
Phase 1 |
Albuterol sulfate |
15 |
Ex Vivo Effect of Fragments and Modified Forms of Surfactant Protein D on Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge in Patients With Asthma and Pilot Study to Assess Local Inflammation Induced by Segmental Allergen Challenge by Magnetic Resonance Imaging |
Completed |
NCT01378624 |
|
|
|